drugset / Trial / NCT00096616

Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma

NCT00096616

Phase 2 Completed 113 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to demonstrate the superior bronchodilator efficacy of inhaled Combivent® CFC MDI vs. Albuterol HFA MDI in moderate to severe asthma patients.

Timeline

Start
2004-11
Primary completion
2006-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipratropium Small molecule
Subject Salbutamol Unknown

Indications